Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)’s Financial Overview
Tetraphase Pharmaceuticals, Inc. (NASDAQ) surged 0% yesterday to close its trading session at $1.49. The company has 1 year Price Target of $6.5. Tetraphase Pharmaceuticals, Inc. has 52-Week high of $6.63 and 52-Week Low of $1.01. The stock touched its 52-Week High on 6.64 and 52-Week Low on 1.01. The stock traded with the volume of 490155 shares yesterday. The firm shows the market capitalization of $79.89 Million.
Tetraphase Pharmaceuticals, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.37/share against the analyst consensus estimate of $-0.36/share. The difference between the actual and expected EPS is $-0.01 a share with a surprise factor of -2.8%.
The firm is trading with SMA20 of 12.2 Percent, SMA50 of -12.2 Percent and SMA200 of -47.63 percent. Tetraphase Pharmaceuticals, Inc. has P/S value of 4.67 while its P/B value stands at 0.81. Similarly, the company has Return on Assets of -58 percent, Return on Equity of -65.9 percent and Return on Investment of -88.7 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for Tetraphase Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 6.00. The median estimate represents a +436.91% increase from the last price of 1.49.
Tetraphase Pharmaceuticals, Inc. is estimated to report earnings on 03/05/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.4. The reported EPS for the same quarter last year was $-0.46.
Cesca Therapeutics Inc. (NASDAQ:KOOL)
Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp., is headquartered in Rancho Cordova, California.
Cesca Therapeutics Inc. (NASDAQ:KOOL)’s Financial Outlook
The 1 analysts offering 12-month price forecasts for Cesca Therapeutics Inc have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +368.75% increase from the last price of 0.32.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, Cesca Therapeutics Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 3.23% and closed its last trading session at $0.32. The company has the market capitalization of $6.7 Million. The stock has 52-week high of $3.34 and 52-Week low of $0.21. The firm touched its 52-Week high on 3.34 and 52-Week low on 0.21. The company has volume of 66886 shares. The company has a total of 20.94 Million shares outstanding.
Cesca Therapeutics Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.12/share where the analyst estimated EPS was $-0.1/share. The difference between the actual and Estimated EPS is $-0.02. This shows a surprise factor of -20 percent.
The company has YTD performance of 19.9 percent. Beta for Cesca Therapeutics Inc. stands at 0.63 while its ATR (average true range) is 0.03. The company has Weekly Volatility of 6.18%% and Monthly Volatility of 12.59%%.
Cesca Therapeutics Inc. has distance from 20-day Simple Moving Average (SMA20) of 15.03%, Distance from 50-Day Simple Moving Average of 6.2 percent and Distance from 200-Day Simple Moving Average of -45.18%.
The Company currently has ROA (Return on Assets) of -97.2 percent, Return on Equity (ROE) of -155.2 Percent and Return on Investment (ROI) of 28% with Gross margin of 26.1 percent and Operating & Profit margin of 0% and 0% respectively.